Bioverativ Reports Second Quarter 2017 Performance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Bioverativ Inc. (BIVV) Tops Q2 EPS by 17c
August 2, 2017 4:51 PM EDTBioverativ Inc. (NASDAQ: BIVV) reported Q2 EPS of $0.88, $0.17 better than the analyst estimate of $0.71. Revenue for the quarter came in at $289.1 million versus the consensus estimate of $268 million.
For earnings history and earnings-related data on Bioverativ Inc. (BIVV) click here.
... More